The semaglutide aging-clock trial

Don't take semaglutide to slow aging on the strength of this trial. It shows that a clock can be nudged in an unusual, fast-aging group at full doses; whether that means a longer or healthier life is unknown, and no randomised trial has tested whether GLP-1 drugs extend healthspan in metabolically healthy adults.

What an aging clock measures

Aging clocks estimate how fast someone is aging from chemical tags (methyl groups) on their DNA. Different clocks emphasise different things: PhenoAge illness and death risk, GrimAge death risk, and DunedinPACE the pace of aging. None of them has been shown to cause anything, so moving a clock is not the same as adding years.

What the trial found

The participants were adults with HIV-associated lipohypertrophy, a redistribution of body fat that comes with HIV, a group that ages biologically faster than the general population. They took weekly semaglutide or placebo for 32 weeks.^[1]

These are rates, epigenetic years gained per calendar year, not years erased over the 32 weeks of dosing.

Clocks for single organ systems all pointed the same way, but only seven of the eleven reached statistical significance. The largest falls, about 5 epigenetic years per calendar year against placebo, were in the inflammation, brain and metabolic clocks; the lung, musculoskeletal, immune and hormone clocks did not move detectably.

Why to read it cautiously

• It wasn't designed to test aging. The clocks were an after-the-fact, exploratory analysis of a 32-week mid-stage trial set up for another purpose.
• It was small: 45 people on semaglutide and 39 on placebo, drawn from people with HIV-related fat redistribution, a group that ages biologically faster — not selected on their clock scores.
• Seventeen clocks were tested with no correction for multiple comparisons, so some of the positive results could be chance.
• A commercial clock company is close to the paper. Two authors work for TruDiagnostic, an epigenetic-testing company, and the first author is its scientific adviser, though the headline clocks are academic ones calculated with public tools.
• The doses were full doses in a non-healthy population. Extrapolating to healthy adults taking 10–25% of that dose, as "microdosing" clinics do, is speculation.

The paper has now passed peer review and been published, which retires the earlier preprint caveat but none of the design ones. The authors themselves ask for validation in broader populations.

How it compares

The best-known other randomised trial to move a methylation clock is a study of calorie restriction in 220 healthy, non-obese adults aged 21–50. Two years of prescribed 25% calorie restriction, of which people managed about half, slowed DunedinPACE by only about 2–3% and moved neither PhenoAge nor GrimAge. That too was an after-the-fact analysis, with the clock's patent-holders among the authors.^[2]

Neither result shows more than that a clock can be nudged. On this evidence semaglutide sits alongside, not above, drugs such as rapamycin and metformin: rich in mechanism, short on hard proof that it slows aging. See Geroprotectors.

What to do

1. Don't start semaglutide for aging alone. The case for it rests on obesity, heart, kidney and metabolic disease, where the outcome trials are; see Ozempic-class drugs.
2. If you take it for those reasons, treat any effect on aging clocks as a possible bonus, not a reason to take it or to stay on a higher dose.
3. Read claims that semaglutide "reverses aging" as resting on this one trial, with the caveats above.

Further reading

• Corley MJ et al. Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy. Nat Commun 2026.^[3]
• Waziry R et al. Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial. Nature Aging 2023.^[4]